

RESEARCH

Open Access



# Clinical implications of peripheral eosinophil count at diagnosis in patients newly diagnosed with microscopic polyangiitis and granulomatosis with polyangiitis

Jang Woo Ha<sup>1</sup>, Sung Soo Ahn<sup>1</sup>, Jason Jungsik Song<sup>1,2</sup>, Yong-Beom Park<sup>1,2</sup> and Sang-Won Lee<sup>1,2\*</sup>

## Abstract

**Background** This study investigated the clinical implications of peripheral eosinophil count at diagnosis in estimating cross-sectional antineutrophil cytoplasmic antibody-associated vasculitis (AAV) activity and predicting all-cause mortality during follow-up in patients newly diagnosed with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA).

**Methods** This study included 224 immunosuppressive drug-naïve patients with peripheral eosinophil count at diagnosis  $< 1,000/\text{mm}^3$ . The Birmingham Vasculitis Activity Score (BVAS), the Five-Factor Score (FFS), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) at diagnosis were assessed.

**Results** The median age of the 224 patients (152 MPA and 72 GPA) was 62.0 years; 35.3% of them were men. At diagnosis, peripheral eosinophil count was significantly correlated with BVAS ( $P=0.001$ ), FFS ( $P=0.046$ ), ESR ( $P<0.001$ ), and CRP ( $P<0.001$ ). Deceased patients had a significantly higher median peripheral eosinophil count at diagnosis than surviving patients ( $310.0/\text{mm}^3$  vs.  $170.0/\text{mm}^3$ ,  $P=0.004$ ). In addition, patients with MPA and those with cardiovascular and renal manifestations at diagnosis exhibited significantly higher peripheral eosinophil counts than those without. When the optimal cut-off of peripheral eosinophil count at diagnosis for all-cause mortality during follow-up was set at  $175.0/\text{mm}^3$ , Patients with peripheral eosinophil count at diagnosis  $\geq 175.0/\text{mm}^3$  exhibited a significantly lower cumulative patients' survival rate than those with peripheral eosinophil count at diagnosis  $< 175.0/\text{mm}^3$  ( $P=0.008$ ).

**Conclusions** This study was the first to demonstrate that peripheral eosinophil count at diagnosis could estimate cross-sectional AAV activity at diagnosis and contribute to predicting all-cause mortality during follow-up in MPA and GPA patients.

**Keywords** Eosinophil, Microscopic polyangiitis, Granulomatosis with polyangiitis, Activity, Mortality

## Background

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterised by necrotising vasculitis of the small vessels with or without granulomatosis or eosinophil infiltration [1]. AAV includes three subtypes: microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with

\*Correspondence:

Sang-Won Lee  
sangwonlee@yuhs.ac

<sup>1</sup> Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

<sup>2</sup> Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

polyangiitis (EGPA) [1, 2]. Among them, an eosinophil-mediated allergic immune mechanism does not play a crucial role in the pathogenesis of MPA and GPA, unlike in EGPA [3, 4]. In addition, in the 2022 American College of Rheumatology (ACR)/ The European Alliance of Associations for Rheumatology classification criteria for MPA and GPA, a negative score is assigned to an item with an increased peripheral eosinophil count [5–7]. Therefore, peripheral eosinophil count does not seem to have a significant clinical implication in patients newly diagnosed with MPA and GPA, versus those with EGPA and allergic diseases [4, 8].

The clinical role of peripheral eosinophil count in the pathogenesis of MPA and GPA has been debated controversially to date: an increased peripheral eosinophil count was reported in the early phases of various acute or chronic diseases other than AAV [9–11], and  $T_{H2}$  cell-mediated immune responses and eosinophil activation in the pathogenesis of MPA and GPA were unveiled [12, 13]. Therefore, it could be assumed that peripheral eosinophils may partially or indirectly affect the pathogenesis of MPA and GPA. However, no study has clarified the clinical implications of peripheral eosinophil count at diagnosis in patients newly diagnosed with MPA and GPA in real clinical settings. Hence, in this study, we investigated the clinical implications of peripheral eosinophil count at diagnosis in estimating cross-sectional AAV activity and predicting all-cause mortality during follow-up in patients newly diagnosed with MPA and GPA.

## Methods

### Patients

This study included 224 patients with MPA and GPA who had peripheral eosinophil count at diagnosis  $< 1,000/\text{mm}^3$ . They were first diagnosed with MPA or GPA at the authors' tertiary university hospital from October 2000 to December 2022. In this study, 'patients newly diagnosed with MPA and GPA' means 'patients who were first diagnosed with MPA and GPA at this hospital'. This is because the variables at diagnosis in patients who were diagnosed with MPA and GPA at other hospitals and receiving immunosuppressive treatment are not reliable and do not meet the purpose of this study. All patients fulfilled the diagnostic algorithm for AAV proposed by the European Medicine Agency in 2007, and the revised Chapel Hill Consensus Conference nomenclature of vasculitides proposed in 2012 [1, 2]. They also met the classification criteria for MPA and GPA suggested by a joint group of the American College of Rheumatology and the European Alliance of Associations for Rheumatology in 2022 [5, 6]. Sufficient medical records data were available for each patient for the collection of clinical, laboratory,

radiological, and histological variables at diagnosis, as well as death or survival during follow-up. The patients were followed up for more than 3 months after AAV diagnosis, did not have concomitant serious medical conditions mimicking AAV at diagnosis, and had not been exposed to glucocorticoids ( $\geq 20$  mg/day prednisolone equivalent) or immunosuppressive drugs within 4 weeks before AAV diagnosis. The present study was approved by the Institutional Review Board (IRB) of Severance Hospital (Seoul, Korea, IRB No. 4–2020-1071), and was conducted according to the Declaration of Helsinki. Given the retrospective design of the study and the use of anonymised patient data, the requirement for written informed consent was waived.

### Clinical and laboratory data at diagnosis

The variables at diagnosis and during follow-up are described in Table 1. Based on the 2022 classification criteria for MPA and GPA, myeloperoxidase (MPO)-ANCA, and proteinase 3 (PR3)-ANCA measured by immunoassays and perinuclear (P)-ANCA, and cytoplasmic (C)-ANCA detected by indirect fluorescence assays were evenly accepted as ANCA positivity [5, 6]. The Birmingham Vasculitis Activity Score (BVAS) and the Five-Factor Score (FFS) at diagnosis were assessed as AAV-specific indices [14, 15]. Data on type 2 diabetes, hypertension, and dyslipidaemia at diagnosis were collected as the initial comorbidities as well as the traditional risk factors for all-cause mortality in addition to age, male sex, body mass index (BMI), and ex-smoker status [16].

### Poor outcomes and follow-up duration

We investigated the incidence of all-cause mortality, relapse, end-stage kidney disease (ESKD), cerebrovascular accident (CVA), and acute coronary syndrome (ACS) during follow-up as poor MPA and GPA outcomes. In terms of the follow-up duration based on each poor outcome, it was defined as the period from diagnosis to each poor outcome in patients with each poor outcome. Whereas, it was defined as the period from diagnosis to the last visit in patients without each poor outcome. We counted the number of patients who received glucocorticoids, cyclophosphamide, rituximab, mycophenolate mofetil, azathioprine, tacrolimus, and methotrexate during follow-up after diagnosis.

### Statistical analyses

All statistical analyses were performed using SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, NY, USA). Continuous variables are expressed as medians (25th–75th percentiles), whereas categorical variables are expressed as numbers (percentages). The correlation coefficient ( $r$ ) between the two variables

**Table 1** Characteristics of patients with MPA and GPA (N=224)

Variables	Values	Variables	Values
<b>At AAV diagnosis</b>		<b>During AAV follow-up</b>	
<b>Demographic data</b>		<b>Poor outcomes (N, (%))</b>	
Age (years)	62.0 (50.0–70.0)	All-cause mortality	36 (16.1)
Male sex (N, (%))	79 (35.3)	Relapse	71 (31.7)
BMI (kg/m <sup>2</sup> )	22.7 (20.5–24.6)	ESKD	53 (23.7)
Ex-smoker (N, (%))	6 (2.7)	CVA	17 (7.6)
		ACS	7 (3.1)
<b>AAV subtype (N, (%))</b>		<b>Follow-up duration based on each poor outcomes (months)</b>	
MPA	152 (67.9)	All-cause mortality	47.8 (12.6–77.5)
GPA	72 (32.1)	Relapse	23.2 (6.1–57.7)
<b>ANCA type and positivity (N, (%))</b>		ESKD	36.0 (6.8–69.6)
MPO-ANCA (or P-ANCA) positivity	164 (73.2)	CVA	40.1 (10.2–75.4)
PR3-ANCA (or C-ANCA) positivity	41 (18.3)	ACS	46.5 (12.0–77.1)
<b>AAV-specific indices</b>		<b>Medications (N, (%))</b>	
BVAS	12.0 (6.3–18.0)	Glucocorticoids	208 (92.9)
FFS	1.0 (0–2.0)	Cyclophosphamide	122 (54.5)
<b>Comorbidities (N, (%))</b>		Rituximab	44 (19.6)
T2DM	65 (29.0)	Mycophenolate mofetil	49 (21.9)
Hypertension	91 (40.6)	Azathioprine	114 (50.9)
Dyslipidaemia	47 (21.0)	Tacrolimus	22 (9.8)
<b>Laboratory results</b>		Methotrexate	23 (10.3)
White blood cell count (/mm <sup>3</sup> )	8,825.0 (6,385.0–12,322.5)		
Neutrophil count (/mm <sup>3</sup> )	6,765.0 (4,335.0–10,155.0)		
Lymphocyte count (/mm <sup>3</sup> )	1,345.0 (932.5–1,867.5)		
Monocyte count (/mm <sup>3</sup> )	450.0 (330.0–597.5)		
Basophil count (/mm <sup>3</sup> )	20.0 (10.0–40.0)		
Haemoglobin (g/dL)	10.9 (9.3–12.8)		
Platelet count (× 1000/mm <sup>3</sup> )	292.0 (223.0–393.8)		
Fasting glucose (mg/dL)	99.0 (90.0–127.0)		
Blood urea nitrogen (mg/dL)	18.4 (13.9–36.6)		
Serum creatinine (mg/dL)	1.0 (0.7–2.1)		
Serum total protein (g/dL)	6.7 (6.0–7.2)		
Serum albumin (g/dL)	3.7 (3.1–4.2)		
ESR (mm/h)	63.0 (23.8–100.3)		
CRP (mg/L)	15.0 (1.7–69.6)		
<b>Eosinophil count (/mm<sup>3</sup>)</b>	<b>190.0 (72.5–360.0)</b>		

MPA Microscopic polyangiitis, GPA Granulomatosis with polyangiitis, BMI Body mass index, MPO Myeloperoxidase, ANCA Antineutrophil cytoplasmic antibody, P Perinuclear, PR3 Proteinase 3, C Cytoplasmic, BVAS Birmingham vasculitis activity score, FFS Five-factor score, T2DM Type 2 diabetes mellitus, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, ESKD End-stage kidney disease, CVA Cerebrovascular accident, ACS Acute coronary syndrome

Values are expressed as a median (25th–75th percentile) or N (%)

was obtained using the Pearson correlation analysis. Significant differences between two continuous variables were compared using the Mann–Whitney U test. The optimal cut-off was extrapolated by the receiver operating characteristic (ROC) curve analysis and one value having the maximised sum of sensitivity and specificity. Comparison of the cumulative

survivals rates between the two groups was analysed by the Kaplan–Meier survival analysis with the log-rank test. The multivariable Cox hazard model using variables with statistical significance in the univariable Cox hazard model was conducted to appropriately obtain the hazard ratios (HRs) during the considerable follow-up duration.  $P < 0.05$  were considered statistically significant.

**Results**

**Characteristics**

At diagnosis, the median age of the 224 patients (152 MPA and 72 GPA) was 62.0 years; 35.3% of them were men. MPO-ANCA (or P-ANCA), and PR3-ANCA (or C-ANCA) were detected in 164 and 41 patients, respectively. The median BVAS, FFS, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels were 12.0, 1.0, 63.0 mm/h, and 15.0 mg/L, respectively. The median peripheral eosinophil count was 190.0/mm<sup>3</sup>. During follow-up, 36 patients died for a median follow-up duration based on all-cause mortality of 47.8 months. Of the 152 and 72 patients with MPA and GPA, 24 and 12 died, respectively, and there was no significant difference in the mortality rates between the two groups (15.8% vs. 16.7%, *P*=0.867). Overall, 71, 53, 17, and seven patients experienced relapse, ESKD, CVA, and ACS, respectively. Glucocorticoids, cyclophosphamide, and azathioprine were administered to 208, 122, and 114 patients, respectively (Table 1).

**Correlation analysis**

At diagnosis, peripheral eosinophil count was significantly correlated with BVAS (*r*=0.214, *P*=0.001), FFS (*r*=0.134, *P*=0.046), ESR (*r*=0.297, *P*<0.001), and CRP (*r*=0.276, *P*<0.001) (Fig. 1).

**Comparison analysis**

Deceased patients had a significantly higher median peripheral eosinophil count at diagnosis than surviving


patients (310.0/mm<sup>3</sup> vs. 170.0/mm<sup>3</sup>, *P*=0.004). At diagnosis, the median peripheral eosinophil count was significantly higher in MPA patients than in GPA patients (200.0/mm<sup>3</sup> vs. 145.0/mm<sup>3</sup>, *P*=0.042). However, no significant differences in peripheral eosinophil counts were observed with respect to sex, MPO-ANCA (or P-ANCA) positivity, or PR3-ANCA (or C-ANCA) positivity. On the other hand, among the BVAS items, patients with cardiovascular and renal manifestations at diagnosis exhibited significantly higher peripheral eosinophil counts than those without them (245.0/mm<sup>3</sup> vs. 170.0/mm<sup>3</sup>, *P*=0.023, and 230.0/mm<sup>3</sup> vs. 110.0/mm<sup>3</sup>, *P*<0.001). (Fig. 2).

**Optimal cut-off**


Using the ROC curve, when the optimal cut-off of peripheral eosinophil count at diagnosis for all-cause mortality during follow-up was set at 175.0/mm<sup>3</sup>, the sensitivity, and specificity were 77.8% and 51.6%, respectively (Fig. 3).

**Comparison of cumulative patients' survival rates**


Patients with peripheral eosinophil count at diagnosis ≥ 175.0/mm<sup>3</sup> exhibited a significantly lower cumulative patients' survival rate than those with peripheral eosinophil count at diagnosis < 175.0/mm<sup>3</sup> (*P*=0.008) (Fig. 4).



**Fig. 1** Correlation analysis of peripheral eosinophil count with BVAS, FFS, ESR, and CRP at diagnosis. BVAS the Birmingham vasculitis activity score, FFS the five-factor score, ESR Erythrocyte sedimentation rate, CRP C-reactive protein



**Fig. 2** Comparison analysis of peripheral eosinophil counts according to death during follow-up, MPA or GPA, and clinical manifestations at diagnosis. *MPA* Microscopic polyangiitis, *GPA* Granulomatosis with polyangiitis




Optimal cut-off of eosinophil count for all-cause mortality 175.0/mm<sup>3</sup> (sensitivity 77.8% and specificity 51.6%)

**Fig. 3** ROC curve analysis for the optimal cut-off of peripheral eosinophil count at diagnosis for all-cause mortality during follow-up. ROC the receiver operating characteristic

**Discussion**

Among the three AAV subtypes, eosinophils are considered more closely associated with EGPA occurrence than with MPA and GPA [4]. According to the new classification criteria for AAV announced in 2022, +5 points were assigned to an item of peripheral eosinophil count at diagnosis  $\geq 1,000/\text{mm}^3$  in the 2022 classification criteria for EGPA, versus, -4 points in the criteria for MPA and GPA [5, 16, 17]. Additionally, according to the treatment guidelines for AAV presented by the ACR in 2021, mepolizumab, which inhibits the signal transduction of interleukin-5, a cytokine closely related to eosinophils only in the treatment algorithm for EGPA, is recommended, unlike MPA and GPA [18]. Therefore, an increase in peripheral eosinophil count in patients newly diagnosed with MPA and GPA might be negligible; however, this study’s findings have the clinical implications.

A previous study reported results contrary to ours including a decrease in peripheral eosinophil count and the expression of altered surface markers of eosinophils in MPA and GPA patients versus healthy controls. However, the most significant difference between the previous



**Fig. 4** Comparison of cumulative patients' survival rates according to peripheral eosinophil count of 175/mm<sup>3</sup>

study and our study was the use of glucocorticoids and immunosuppressive drugs. Because the previous study included patients taking therapeutic drugs, it was difficult to rule out the possibility that those drugs might have an influence on decreased peripheral eosinophil count in the group of MPA and GPA patients [19]. However, because our study included only patients who had not been exposed to those drugs within 4 weeks before AAV diagnosis, confounding variables due to glucocorticoids and immunosuppressive drugs might be minimised or nullified. In addition, they did not provide information on the association between peripheral eosinophil count and cross-sectional AAV activity at diagnosis or poor outcomes during follow-up [19]. To overcome these limitations, this study investigated the clinical implications of peripheral eosinophil count at diagnosis in immunosuppressive drug-naïve patients newly diagnosed with MPA and GPA and demonstrated that it could estimate cross-sectional AAV activity and predict all-cause mortality during follow-up.

To investigate the concordance or discordance of the results of the correlation analyses according to AAV subtypes, we performed the correlation analyses separately in patients with MPA and those with GPA. Among the 152 patients with MPA, peripheral eosinophil count was significantly correlated with BVAS ( $r=0.188$ ,  $P=0.021$ ), ESR ( $r=0.333$ ,  $P<0.001$ ), and CRP ( $r=0.241$ ,  $P=0.003$ ) but not FFS. Whereas, among the 72 patients with GPA, peripheral eosinophil count was significantly correlated with only CRP ( $r=0.372$ ,  $P=0.001$ ). On the other hand,

peripheral eosinophil count tended to be correlated with BVAS but it was not statistically significant ( $r=0.197$ ,  $P=0.097$ ). Despite the discordance of the correlation pattern, between MPA and GPA patients, given that in real clinical settings, there are patients classified as both MPA and GPA, patients with unclear boundaries between MPA and GPA, and those whose MPA and GPA diagnoses change over time, we believe that these results may support that peripheral eosinophil count at diagnosis could reflect cross-sectional BVAS and CRP regardless of MPA or GPA patients.

We wondered about the mechanism of the predictive ability of peripheral eosinophil count at diagnosis for all-cause mortality during follow-up in patients newly diagnosed with MPA and GPA, and suggested two hypotheses. The first hypothesis was based on the initial disease activity of MPA and GPA at diagnosis. In this study, we showed that at the time of diagnosis, peripheral eosinophil count was significantly correlated with cross-sectional BVAS and FFS, well-known predictors of all-cause mortality in AAV patients [20, 21]. Moreover, we found that it was significantly correlated with ESR and CRP levels at diagnosis, which could simultaneously reflect the inflammatory burden of AAV [22]. The second hypothesis was related to chemotactic factors of eosinophils. In the pathogenesis of MPA and GPA, interleukin-8, C3a, and C5a are key molecules that can activate and recruit neutrophils to inflamed tissues, leading to a vicious cycle and aggravated disease course [3, 23]. These factors are also known as chemotactic factors

for eosinophils [24–26]. Therefore, high levels of inflammation that may enhance the production of eosinophil chemotactic factors may subsequently increase not only peripheral eosinophil count but also the likelihood of all-cause mortality.

Another possibility is that the immune properties of EGPA partially contribute to those of MPA and GPA in newly diagnosed patients. In fact, there has been a movement to understand EGPA as a disease that shares parts with GPA, MPA, polyangiitis overlap syndrome, and hypereosinophilic syndrome, rather than as an independent and sequestered disease [27]. While the result that peripheral eosinophil count was elevated in patients with MPA or renal manifestation may support the two hypotheses mentioned above, the result of the same pattern in patients with cardiovascular manifestation may imply the effect of partially overlapping EGPA (Fig. 2). However, since cardiac magnetic resonance imaging was not performed in all patients with cardiovascular manifestation, and thus, it was impossible to clearly provide objective evidence of eosinophilic myocarditis, we could not insist on this context as a hypothesis; rather, we just suggest its possibility.

Here, we attempted to elucidate the independent predictive potential of peripheral eosinophil count at diagnosis for all-cause mortality among the variables at diagnosis using the Cox hazards model analyses. In the univariable analysis, age, male sex, BMI, BVAS, FFS, dyslipidaemia, white blood cell count, haemoglobin, blood urea nitrogen, serum creatinine, serum total protein, serum albumin, CRP, and peripheral eosinophil count  $\geq 175.0/\text{mm}^3$  were significantly associated with all-cause mortality in patients newly diagnosed with MPA and GPA. In contrast, the continuous variable of peripheral eosinophil count was not associated with all-cause mortality ( $P=0.098$ ).

In the multivariable analysis, male sex (HR 3.463, 95% confidence interval [CI] 1.561, 7.682), BVAS (HR 1.076, 95% CI 1.015, 1.141), FFS (HR 1.560, 95% CI 1.043, 2.332), dyslipidaemia (HR 3.349, 95% CI 1.497, 7.493), and serum albumin (HR 0.377, 95% CI 0.180, 0.789) were independently associated with all-cause mortality in patients newly diagnosed with MPA and GPA, whereas peripheral eosinophil count  $\geq 175.0/\text{mm}^3$  was not (see Additional file 1). Therefore, it was concluded that peripheral eosinophil count at diagnosis had the ability to predict all-cause mortality during follow-up, but did not have strong predictive potential comparable to those of traditional risk factors in patients newly diagnosed with MPA and GPA.

Given that the normal peripheral eosinophil count is  $\leq 500/\text{mm}^3$ , only 197 patients newly diagnosed with MPA and GPA who had peripheral eosinophil count at

diagnosis  $\leq 500/\text{mm}^3$  were re-analysed. Using the ROC curve, when the optimal cut-off of peripheral eosinophil count at diagnosis for all-cause mortality was set at  $\geq 165.0/\text{mm}^3$ , the sensitivity and specificity were 75.9% and 46.4%, respectively (see Additional file 2A). Patients with peripheral eosinophil count at diagnosis  $\geq 165.0/\text{mm}^3$  exhibited a significantly reduced cumulative patients' survival rate compared to those with peripheral eosinophil count at diagnosis  $< 165.0/\text{mm}^3$  (see Additional file 2B). Therefore, regardless of the absolute normal range of peripheral eosinophil count ( $500/\text{mm}^3$ ) or the range for EGPA exclusion ( $1,000/\text{mm}^3$ ), peripheral eosinophil count at diagnosis showed a pattern similar to the conclusions of this study.

The strength of this study is that it is the first to demonstrate that peripheral eosinophil count at diagnosis can estimate cross-sectional AAV activity and predict all-cause mortality during follow-up in patients newly diagnosed with MPA and GPA. This study has several limitations. The first limitation is the retrospective study design. Because of this study design, we could not completely control for conditions that could cause an increase in peripheral eosinophil count, such as the history of allergic diseases, history of taking medications other than glucocorticoids and immunosuppressive drugs, and the presence or absence of parasitic infections in all included patients. The second limitation is the relatively small number of patients newly diagnosed with MPA and GPA. Because of this limitation, it seems uneasy to generalise the results of this study. The third limitation is not performing validation analysis. Since there are few tertiary hospitals operating the observational and systemic cohorts of Korean patients with AAV except this hospital, it was not possible to perform an additional analysis through a validation cohort considering ethnic and geographical features. Nevertheless, this study has clinical significance in that it unveiled the association of peripheral eosinophil count with AAV activity at diagnosis and all-cause mortality during follow-up in patients newly diagnosed with MPA and GPA as a pilot study. We believe that a future prospective study including more patients will provide more reliable information on the clinical implications of peripheral eosinophil count at diagnosis in patients newly diagnosed with MPA and GPA.

## Conclusions

This study was the first to demonstrate that peripheral eosinophil count at diagnosis could estimate cross-sectional AAV activity at diagnosis and contribute to predicting all-cause mortality during follow-up in patients newly diagnosed with MPA and GPA other than EGPA.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13075-023-03233-1>.

**Additional file 1.** Cox hazards model analyses of eosinophil count and variables at diagnosis for all-cause mortality during follow-up in MPA and GPA patients

**Additional file 2.** ROC curve analysis for the optimal cut-off of peripheral eosinophil count at diagnosis for all-cause mortality during follow-up and comparison of cumulative patients' survival rates according to peripheral eosinophil count of  $165/\text{mm}^3$  in MPA and GPA patients who had peripheral eosinophil count at diagnosis  $\leq 500/\text{mm}^3$

### Acknowledgements

None

### Authors' contributions

J.W.H. and S.W.L. conceived and designed the study, wrote the draft and reviewed the draft. J.W.H., S.S.A., J.J.S. and S.W.L. screened the abstracts and full texts, extracted data, assessed studies, and performed statistical analyses. J.J.S. and Y.B.P. assisted in statistical analyses. All authors read the draft and approved the final version of the manuscript.

### Funding

This study was supported by a faculty research grant of Yonsei University College of Medicine, Seoul, Republic of Korea (6–2023-0155), and CELLTRION PHARM, Inc. Chungcheongbuk-do, Republic of Korea (NCR 2019–6). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. All authors declare no other competing interests.

### Availability of data and materials

Additional data are available on request.

### Declarations

#### Ethics approval and consent to participate

The present study was approved by the Institutional Review Board (IRB) of Severance Hospital (Seoul, Korea, IRB No. 4–2020-1071), and was conducted according to the Declaration of Helsinki. Given the retrospective design of the study and the use of anonymised patient data, the requirement for written informed consent was waived.

#### Consent for publication

Not required.

#### Provenance and peer review

Not commissioned; externally peer reviewed.

#### Competing interests

The authors declare no competing interests.

Received: 15 May 2023 Accepted: 6 December 2023

Published online: 15 December 2023

### References

- Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum.* 2013;65:1–11.
- Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Ann Rheum Dis.* 2007;66:222–7.
- Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis *Nat Rev Dis Primers.* 2020;6:71.
- Choi CB, Park YB, Lee SW. Eosinophilic Granulomatosis with Polyangiitis: Experiences in Korean Patients. *Yonsei Med J.* 2019;60:705–12.
- Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. *Ann Rheum Dis.* 2022;81:321–6.
- Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. *Ann Rheum Dis.* 2022;81:315–20.
- Pyo JY, Lee LE, Park YB, Lee SW. Comparison of the 2022 ACR/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Previous Criteria. *Yonsei Med J.* 2023;64:11–7.
- Hospers JJ, Schouten JP, Weiss ST, Postma DS, Rijcken B. Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample. *Epidemiology.* 2000;11:261–8.
- Cikrikioglu MA, Soysal P, Dikerdem D, Cakirca M, Kazancioglu R, Yolbas S, et al. Absolute blood eosinophil count and 1-year mortality risk following hospitalization with acute heart failure. *Eur J Emerg Med.* 2012;19:257–63.
- Gonzalez Gomez H, Savarraj J, Paz AS, Ren X, Chen H, McCullough LD, et al. Peripheral eosinophil trends and clinical outcomes after non-traumatic subarachnoid hemorrhage. *Front Neurol.* 2023;14:1051732.
- Escobar-Valdivia EJ, González-Aguirre JE, Carrillo-Cisneros ER, Guerra-Leza KC, Mercado-Longoria R. Eosinophil count at intensive care unit admission was not predictor of hospital mortality: results of a case control study. *J Intensive Care.* 2015;3:27.
- Balding CE, Howie AJ, Drake-Lee AB, Savage CO. Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. *Clin Exp Immunol.* 2001;125:332–9.
- Choopong P, Khan N, Sangwan VS, Zafirakis P, Rallatos CL, Rojas B, et al. Eosinophil activation in Wegener's granulomatosis: a harbinger of disease progression? *Ocul Immunol Inflamm.* 2005;13:439–45.
- Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). *Ann Rheum Dis.* 2009;68:1827–32.
- Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. *Medicine (Baltimore).* 2011;90:19–27.
- Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. *JAMA.* 2013;310:591–608.
- Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. *Ann Rheum Dis.* 2022;81:309–14.
- Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *Arthritis Rheumatol.* 2021;73:1366–83.
- Hellmark T, Ohlsson S, Pettersson Å, Hansson M, Johansson ÅCM. Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis. *BMC Rheumatol.* 2019;3:9.
- Dagostin MA, Nunes SLO, Shinjo SK, Pereira RMR. Mortality predictors in ANCA-associated vasculitis: Experience of a Brazilian monocentric cohort of a rheumatology center. *Medicine (Baltimore).* 2021;100:e28305.
- Vega LE, Espinoza LR. Predictors of Poor Outcome in ANCA-Associated Vasculitis (AAV). *Curr Rheumatol Rep.* 2016;18:70.
- Park PG, Song JJ, Park YB, Lee SW. Clinical application of low erythrocyte sedimentation rate/high C-reactive protein to antineutrophil cytoplasmic antibody-associated vasculitis. *J Clin Lab Anal.* 2022;36:e24237.
- Choi CB, Park YB, Lee SW. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Korea: A Narrative Review. *Yonsei Med J.* 2019;60:10–21.

24. Erger RA, Casale TB. Interleukin-8 is a potent mediator of eosinophil chemotaxis through endothelium and epithelium. *Am J Physiol.* 1995;268:L117–22.
25. Daffern PJ, Pfeifer PH, Ember JA, Hugli TE. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. *J Exp Med.* 1995;181:2119–27.
26. Resnick MB, Weller PF. Mechanisms of eosinophil recruitment. *Am J Respir Cell Mol Biol.* 1993;8:349–55.
27. Gauckler P, Shin JI, Mayer G, Kronbichler A. Eosinophilia and Kidney Disease: More than Just an Incidental Finding? *J Clin Med.* 2018;7:529.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

